10x GenomicsTXG recently announced the commercial launch of Sentira Single Cell, a cloud-based agentic AI application designed to simplify the analysis of Chromium single-cell data. Powered by Anthropic's Claude models, the application allows researchers to ask scientific questions, explore datasets and test hypotheses using natural language. Its AI agent develops and executes analysis plans, returning documented results to help researchers move efficiently from complex biological data to experimental conclusions.
Per management, Sentira Single Cell addresses the longstanding challenge of translating generated data into answers to specific scientific questions. By combining agentic AI with the company's expertise in single-cell biology, Chromium data and analytical workflows, the application is designed to make sophisticated data analysis accessible to a broader research community.
TXG Stock Trend Following the News
Year to date, the stock skyrocketed 256%, outperforming the industry's 19.8% growth and the S&P 500's 6.8% gain.
The launch could strengthen 10x Genomics' position in the life science technology market by helping researchers overcome the challenges of translating complex biological datasets into scientific insights. By reducing the time and expertise required to analyze and interpret data, Sentira Single Cell could help accelerate hypothesis testing and improve research productivity. This may broaden the appeal of AI-assisted data analysis among academic institutions, pharmaceutical companies and biotechnology researchers. Wider adoption may also create a source of recurring, usage-based revenues for TXG while extending its presence in the AI-enabled life sciences market.
TXG currently has a market capitalization of $8.80 billion.
Image Source: Zacks Investment Research
More on the Sentira Single Cell Application
Sentira Single Cell enables researchers to submit scientific questions or ask the AI agent to propose hypotheses based on their data. The agent creates an analysis plan for researchers to review and refine before executing the requested work. Results are captured in an editable, reproducible notebook that documents the methods and code used, allowing scientists to maintain transparency and control over the analytical process. Researchers can continue interacting with the agent to explore additional questions and modify their analyses.
Built on 10x Cloud, the application provides computing resources to analyze Chromium datasets of varying sizes and run multiple analyses in parallel without requiring users to configure or manage their own infrastructure. It is available commercially, with promotional credits for new users and consumption-based pricing that scales with analysis requirements.
The launch builds on 10x Genomics' existing collaboration with Anthropic, announced in October 2025. Through that partnership, the companies sought to make TXG's single-cell and spatial biology tools accessible through Claude for Life Sciences, using the Model Context Protocol to enable researchers to explore complex datasets conversationally.
Sentira Single Cell advances this collaboration by bringing Claude-powered agentic reasoning into a dedicated application for Chromium analysis. The launch also expands the Sentira platform, introduced in late September with Sentira Spatial Analysis in early access, supporting 10x Genomics' broader effort to simplify the interpretation of complex biological data.
Industry Prospects Favoring the Market
According to Grand View Research, the global single-cell analysis market is estimated to reach $6.5 billion in 2026 and is projected to witness a CAGR of 21.7% through 2033.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools, and rising demand for precision medicine and oncology research are boosting the market's growth.
Other News
10x Genomics recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia (AML), marking TXG's first clinical research initiative into hematologic malignancies.
10x Genomics announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes.
10x Genomics began commercial shipments of Atera, its next-generation spatial biology platform designed to combine whole-transcriptome analysis, sub-cellular resolution and single-cell sensitivity at scale.
10x Genomics Price
10x Genomics price | 10x Genomics Quote
TXG's Zacks Rank & Other Key Picks
Currently, 10x Genomics carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are GlaukosGKOS, Intuitive SurgicalISRG and West Pharmaceutical ServicesWST.
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today's Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company's earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
10x Genomics (TXG) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
Glaukos Corporation (GKOS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
